Anticancer effect of combination therapy of VP16 and fosfesterol in hormone-refractory prostate cancer

Haruhito Azuma, Takeshi Sakamoto, Satoshi Kiyama, Takanobu Ubai, Yatsugu Kotake, Teruo Inamoto, Kiyoshi Takahara, Yasuichiro Nishimura, Naoki Segawa, Yoji Katsuoka

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

OBJECTIVES: We conducted the present study to evaluate the safety profile and therapeutic value of a combination of etoposide and fosfestrol for treatment of hormone-refractory prostate cancer (HRPC). METHODS: Forty patients with HRPC were included in the study. The median age was 71 years (range, 50-86 years), the Gleason's score ranged from 5 to 10, and the median prostate-specific antigen level was 62.6 ng/mL (range, 4.738-30789 ng/mL). The patients received oral etoposide 25 mg/d and fosfestrol 300 mg/d. RESULTS: The response rate in terms of measurable disease, serum prostate-specific antigen level, and overall evaluation was 36.8% (CR: 18.4%; PR: 18.4%), 80% (CR: 55%; PR: 25%), and 40% (CR: 20%; PR: 20%) with a median duration of response of 13.6, 13.5, and 13.5 months, respectively. An objective clinical response for overall evaluation was shown by 90% (CR: 20%; PR: 20%; SD: 50%) of the patients, with a median response duration of 15.7 months; 16 patients (40%) are currently alive without recurrence after a median follow-up period of 21.2 months. The overall survival and progression-free survival was 30.5% and 28.8% at 40 months, respectively. No grade III toxicities occurred in any of the patients. Serial measurements in 34 patients using the Functional Assessment of Cancer Therapy-Prostate showed a significant improvement in quality of life as a result of the therapy. CONCLUSIONS: The combination of oral etoposide and fosfestrol is active in patients with HRPC. The regimen is tolerable and has a significant impact on quality of life as measured by the Functional Assessment of Cancer Therapy-Prostate in a limited sample of patients.

Original languageEnglish
Pages (from-to)188-194
Number of pages7
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume31
Issue number2
DOIs
Publication statusPublished - 01-04-2008
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Hormones
Etoposide
Therapeutics
Prostate-Specific Antigen
Quality of Life
fosfestrol
Neoplasm Grading
Disease-Free Survival
Safety
Recurrence
Survival
Serum

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Azuma, Haruhito ; Sakamoto, Takeshi ; Kiyama, Satoshi ; Ubai, Takanobu ; Kotake, Yatsugu ; Inamoto, Teruo ; Takahara, Kiyoshi ; Nishimura, Yasuichiro ; Segawa, Naoki ; Katsuoka, Yoji. / Anticancer effect of combination therapy of VP16 and fosfesterol in hormone-refractory prostate cancer. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2008 ; Vol. 31, No. 2. pp. 188-194.
@article{9b68695251724b5a9e6f0f696bcf1433,
title = "Anticancer effect of combination therapy of VP16 and fosfesterol in hormone-refractory prostate cancer",
abstract = "OBJECTIVES: We conducted the present study to evaluate the safety profile and therapeutic value of a combination of etoposide and fosfestrol for treatment of hormone-refractory prostate cancer (HRPC). METHODS: Forty patients with HRPC were included in the study. The median age was 71 years (range, 50-86 years), the Gleason's score ranged from 5 to 10, and the median prostate-specific antigen level was 62.6 ng/mL (range, 4.738-30789 ng/mL). The patients received oral etoposide 25 mg/d and fosfestrol 300 mg/d. RESULTS: The response rate in terms of measurable disease, serum prostate-specific antigen level, and overall evaluation was 36.8{\%} (CR: 18.4{\%}; PR: 18.4{\%}), 80{\%} (CR: 55{\%}; PR: 25{\%}), and 40{\%} (CR: 20{\%}; PR: 20{\%}) with a median duration of response of 13.6, 13.5, and 13.5 months, respectively. An objective clinical response for overall evaluation was shown by 90{\%} (CR: 20{\%}; PR: 20{\%}; SD: 50{\%}) of the patients, with a median response duration of 15.7 months; 16 patients (40{\%}) are currently alive without recurrence after a median follow-up period of 21.2 months. The overall survival and progression-free survival was 30.5{\%} and 28.8{\%} at 40 months, respectively. No grade III toxicities occurred in any of the patients. Serial measurements in 34 patients using the Functional Assessment of Cancer Therapy-Prostate showed a significant improvement in quality of life as a result of the therapy. CONCLUSIONS: The combination of oral etoposide and fosfestrol is active in patients with HRPC. The regimen is tolerable and has a significant impact on quality of life as measured by the Functional Assessment of Cancer Therapy-Prostate in a limited sample of patients.",
author = "Haruhito Azuma and Takeshi Sakamoto and Satoshi Kiyama and Takanobu Ubai and Yatsugu Kotake and Teruo Inamoto and Kiyoshi Takahara and Yasuichiro Nishimura and Naoki Segawa and Yoji Katsuoka",
year = "2008",
month = "4",
day = "1",
doi = "10.1097/COC.0b013e3181595af6",
language = "English",
volume = "31",
pages = "188--194",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

Anticancer effect of combination therapy of VP16 and fosfesterol in hormone-refractory prostate cancer. / Azuma, Haruhito; Sakamoto, Takeshi; Kiyama, Satoshi; Ubai, Takanobu; Kotake, Yatsugu; Inamoto, Teruo; Takahara, Kiyoshi; Nishimura, Yasuichiro; Segawa, Naoki; Katsuoka, Yoji.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 31, No. 2, 01.04.2008, p. 188-194.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Anticancer effect of combination therapy of VP16 and fosfesterol in hormone-refractory prostate cancer

AU - Azuma, Haruhito

AU - Sakamoto, Takeshi

AU - Kiyama, Satoshi

AU - Ubai, Takanobu

AU - Kotake, Yatsugu

AU - Inamoto, Teruo

AU - Takahara, Kiyoshi

AU - Nishimura, Yasuichiro

AU - Segawa, Naoki

AU - Katsuoka, Yoji

PY - 2008/4/1

Y1 - 2008/4/1

N2 - OBJECTIVES: We conducted the present study to evaluate the safety profile and therapeutic value of a combination of etoposide and fosfestrol for treatment of hormone-refractory prostate cancer (HRPC). METHODS: Forty patients with HRPC were included in the study. The median age was 71 years (range, 50-86 years), the Gleason's score ranged from 5 to 10, and the median prostate-specific antigen level was 62.6 ng/mL (range, 4.738-30789 ng/mL). The patients received oral etoposide 25 mg/d and fosfestrol 300 mg/d. RESULTS: The response rate in terms of measurable disease, serum prostate-specific antigen level, and overall evaluation was 36.8% (CR: 18.4%; PR: 18.4%), 80% (CR: 55%; PR: 25%), and 40% (CR: 20%; PR: 20%) with a median duration of response of 13.6, 13.5, and 13.5 months, respectively. An objective clinical response for overall evaluation was shown by 90% (CR: 20%; PR: 20%; SD: 50%) of the patients, with a median response duration of 15.7 months; 16 patients (40%) are currently alive without recurrence after a median follow-up period of 21.2 months. The overall survival and progression-free survival was 30.5% and 28.8% at 40 months, respectively. No grade III toxicities occurred in any of the patients. Serial measurements in 34 patients using the Functional Assessment of Cancer Therapy-Prostate showed a significant improvement in quality of life as a result of the therapy. CONCLUSIONS: The combination of oral etoposide and fosfestrol is active in patients with HRPC. The regimen is tolerable and has a significant impact on quality of life as measured by the Functional Assessment of Cancer Therapy-Prostate in a limited sample of patients.

AB - OBJECTIVES: We conducted the present study to evaluate the safety profile and therapeutic value of a combination of etoposide and fosfestrol for treatment of hormone-refractory prostate cancer (HRPC). METHODS: Forty patients with HRPC were included in the study. The median age was 71 years (range, 50-86 years), the Gleason's score ranged from 5 to 10, and the median prostate-specific antigen level was 62.6 ng/mL (range, 4.738-30789 ng/mL). The patients received oral etoposide 25 mg/d and fosfestrol 300 mg/d. RESULTS: The response rate in terms of measurable disease, serum prostate-specific antigen level, and overall evaluation was 36.8% (CR: 18.4%; PR: 18.4%), 80% (CR: 55%; PR: 25%), and 40% (CR: 20%; PR: 20%) with a median duration of response of 13.6, 13.5, and 13.5 months, respectively. An objective clinical response for overall evaluation was shown by 90% (CR: 20%; PR: 20%; SD: 50%) of the patients, with a median response duration of 15.7 months; 16 patients (40%) are currently alive without recurrence after a median follow-up period of 21.2 months. The overall survival and progression-free survival was 30.5% and 28.8% at 40 months, respectively. No grade III toxicities occurred in any of the patients. Serial measurements in 34 patients using the Functional Assessment of Cancer Therapy-Prostate showed a significant improvement in quality of life as a result of the therapy. CONCLUSIONS: The combination of oral etoposide and fosfestrol is active in patients with HRPC. The regimen is tolerable and has a significant impact on quality of life as measured by the Functional Assessment of Cancer Therapy-Prostate in a limited sample of patients.

UR - http://www.scopus.com/inward/record.url?scp=42049092408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42049092408&partnerID=8YFLogxK

U2 - 10.1097/COC.0b013e3181595af6

DO - 10.1097/COC.0b013e3181595af6

M3 - Article

C2 - 18391605

AN - SCOPUS:42049092408

VL - 31

SP - 188

EP - 194

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 2

ER -